Shots:
Sandoz & Polpharma have launched Tyruko, a biosimilar version of Biogen’s Tysabri (natalizumab), for all indications of the reference product, incl. relapsing forms of multiple sclerosis (MS) & mod. to sev. active Crohn’s disease in adults
In 2019, Sandoz signed a global commercialization deal with Polpharma for Tyruko, with Polpharma responsible for development &…
